 Elisa Birnbaum
Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 37 | 2023 | 136 | 2.860 |
Why?
| | Adenocarcinoma | 24 | 2023 | 898 | 0.970 |
Why?
| | Fecal Incontinence | 11 | 2020 | 80 | 0.790 |
Why?
| | Laparoscopy | 14 | 2019 | 449 | 0.770 |
Why?
| | Colorectal Surgery | 5 | 2022 | 22 | 0.700 |
Why?
| | Neoadjuvant Therapy | 12 | 2023 | 381 | 0.690 |
Why?
| | Colectomy | 13 | 2022 | 93 | 0.590 |
Why?
| | Pelvic Floor Disorders | 3 | 2020 | 9 | 0.500 |
Why?
| | Anal Canal | 10 | 2014 | 88 | 0.480 |
Why?
| | Rectal Prolapse | 5 | 2020 | 21 | 0.470 |
Why?
| | Neoplasm Recurrence, Local | 18 | 2019 | 958 | 0.470 |
Why?
| | Neoplasm Staging | 25 | 2023 | 1290 | 0.420 |
Why?
| | Digestive System Surgical Procedures | 6 | 2020 | 96 | 0.410 |
Why?
| | Proctocolectomy, Restorative | 5 | 2016 | 19 | 0.380 |
Why?
| | Anus Neoplasms | 6 | 2009 | 30 | 0.340 |
Why?
| | Rectum | 6 | 2016 | 170 | 0.320 |
Why?
| | Patient Reported Outcome Measures | 3 | 2020 | 372 | 0.290 |
Why?
| | Training Support | 1 | 2007 | 28 | 0.270 |
Why?
| | Certification | 1 | 2007 | 94 | 0.250 |
Why?
| | Colonic Neoplasms | 5 | 2013 | 242 | 0.250 |
Why?
| | Treatment Outcome | 34 | 2023 | 10202 | 0.250 |
Why?
| | Middle Aged | 57 | 2022 | 31091 | 0.250 |
Why?
| | Postoperative Complications | 16 | 2022 | 2473 | 0.250 |
Why?
| | Pelvic Floor | 3 | 2020 | 22 | 0.240 |
Why?
| | Fluorouracil | 8 | 2014 | 198 | 0.230 |
Why?
| | Colitis, Ulcerative | 4 | 2016 | 118 | 0.230 |
Why?
| | Aged, 80 and over | 33 | 2020 | 7055 | 0.230 |
Why?
| | Rectal Fistula | 4 | 2013 | 21 | 0.220 |
Why?
| | Aged | 45 | 2020 | 22032 | 0.220 |
Why?
| | Preoperative Care | 7 | 2014 | 339 | 0.220 |
Why?
| | Retrospective Studies | 34 | 2023 | 14461 | 0.210 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 273 | 0.210 |
Why?
| | Societies, Medical | 3 | 2020 | 744 | 0.210 |
Why?
| | Male | 62 | 2022 | 63517 | 0.200 |
Why?
| | Female | 65 | 2022 | 68556 | 0.200 |
Why?
| | Consensus | 3 | 2020 | 615 | 0.200 |
Why?
| | Colonic Pouches | 2 | 2013 | 14 | 0.190 |
Why?
| | Brachytherapy | 2 | 2001 | 104 | 0.190 |
Why?
| | Radiotherapy, Adjuvant | 11 | 2019 | 208 | 0.190 |
Why?
| | Pelvic Organ Prolapse | 2 | 2020 | 45 | 0.180 |
Why?
| | Radiation Injuries | 4 | 2009 | 135 | 0.180 |
Why?
| | Adult | 47 | 2020 | 35497 | 0.180 |
Why?
| | Humans | 75 | 2023 | 129271 | 0.170 |
Why?
| | Disease-Free Survival | 13 | 2019 | 645 | 0.170 |
Why?
| | Manometry | 7 | 2006 | 91 | 0.170 |
Why?
| | Follow-Up Studies | 17 | 2019 | 4887 | 0.160 |
Why?
| | Pneumoperitoneum | 1 | 2019 | 12 | 0.160 |
Why?
| | Combined Modality Therapy | 12 | 2016 | 1199 | 0.160 |
Why?
| | Urology | 1 | 2020 | 56 | 0.160 |
Why?
| | Skiing | 1 | 2019 | 44 | 0.150 |
Why?
| | Urologic Surgical Procedures | 1 | 2020 | 107 | 0.150 |
Why?
| | Radiotherapy | 3 | 2003 | 185 | 0.150 |
Why?
| | Laparotomy | 2 | 2015 | 106 | 0.150 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2023 | 41 | 0.150 |
Why?
| | Radiotherapy Dosage | 8 | 2009 | 251 | 0.150 |
Why?
| | Medicine | 1 | 2019 | 119 | 0.140 |
Why?
| | Propensity Score | 1 | 2019 | 263 | 0.140 |
Why?
| | Gynecology | 1 | 2020 | 174 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2009 | 625 | 0.140 |
Why?
| | Internship and Residency | 1 | 2007 | 1047 | 0.130 |
Why?
| | Crohn Disease | 4 | 2019 | 215 | 0.130 |
Why?
| | Perineum | 3 | 2008 | 26 | 0.120 |
Why?
| | Surgeons | 1 | 2019 | 260 | 0.120 |
Why?
| | Prospective Studies | 14 | 2014 | 7123 | 0.120 |
Why?
| | Quality of Life | 4 | 2020 | 2687 | 0.120 |
Why?
| | Antimetabolites, Antineoplastic | 4 | 2002 | 91 | 0.110 |
Why?
| | Anastomotic Leak | 1 | 2014 | 38 | 0.110 |
Why?
| | Radiopharmaceuticals | 3 | 2006 | 168 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2006 | 128 | 0.110 |
Why?
| | Survival Analysis | 8 | 2016 | 1269 | 0.110 |
Why?
| | Postoperative Care | 2 | 2013 | 241 | 0.110 |
Why?
| | Fistula | 1 | 2013 | 35 | 0.100 |
Why?
| | Colostomy | 2 | 2012 | 26 | 0.100 |
Why?
| | Defecation | 1 | 1992 | 19 | 0.100 |
Why?
| | Bioprosthesis | 1 | 2012 | 40 | 0.100 |
Why?
| | Severity of Illness Index | 5 | 2013 | 2740 | 0.090 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 49 | 0.090 |
Why?
| | Diverticulitis, Colonic | 1 | 2011 | 7 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 320 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2023 | 379 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2011 | 470 | 0.090 |
Why?
| | Radiotherapy, High-Energy | 2 | 2001 | 13 | 0.090 |
Why?
| | Rosaniline Dyes | 1 | 2010 | 12 | 0.080 |
Why?
| | Salvage Therapy | 2 | 2009 | 133 | 0.080 |
Why?
| | Time Factors | 9 | 2015 | 6543 | 0.080 |
Why?
| | Coloring Agents | 1 | 2010 | 77 | 0.080 |
Why?
| | Rectal Diseases | 2 | 2002 | 19 | 0.080 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 219 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1556 | 0.080 |
Why?
| | Urodynamics | 2 | 2020 | 35 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2010 | 107 | 0.080 |
Why?
| | Tomography, Emission-Computed | 2 | 2000 | 66 | 0.080 |
Why?
| | Chi-Square Distribution | 4 | 2011 | 514 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2023 | 208 | 0.070 |
Why?
| | Proportional Hazards Models | 5 | 2008 | 1197 | 0.070 |
Why?
| | Adenoma | 1 | 2010 | 214 | 0.070 |
Why?
| | Survival Rate | 5 | 2011 | 1869 | 0.070 |
Why?
| | Colonoscopy | 1 | 2010 | 236 | 0.070 |
Why?
| | Length of Stay | 4 | 2015 | 1120 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 4 | 2011 | 2515 | 0.070 |
Why?
| | Intestines | 1 | 2010 | 347 | 0.070 |
Why?
| | Ultrasonography | 4 | 2005 | 713 | 0.070 |
Why?
| | Vaginal Fistula | 2 | 2013 | 3 | 0.070 |
Why?
| | Prosthesis Implantation | 2 | 2012 | 143 | 0.070 |
Why?
| | United States | 6 | 2020 | 13828 | 0.070 |
Why?
| | Specialty Boards | 1 | 2007 | 32 | 0.070 |
Why?
| | Liver Neoplasms | 2 | 2010 | 640 | 0.060 |
Why?
| | Anesthesia, Local | 2 | 2003 | 16 | 0.060 |
Why?
| | Age Factors | 5 | 2013 | 3140 | 0.060 |
Why?
| | Research Support as Topic | 1 | 2007 | 111 | 0.060 |
Why?
| | Ileostomy | 3 | 2011 | 20 | 0.060 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 768 | 0.060 |
Why?
| | Analysis of Variance | 5 | 2011 | 1288 | 0.060 |
Why?
| | Anastomosis, Surgical | 3 | 2013 | 149 | 0.060 |
Why?
| | Ileitis | 1 | 2006 | 32 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 509 | 0.060 |
Why?
| | Bowen's Disease | 1 | 2004 | 1 | 0.060 |
Why?
| | Anus Diseases | 1 | 2004 | 7 | 0.060 |
Why?
| | Mentors | 1 | 2007 | 178 | 0.060 |
Why?
| | Recurrence | 4 | 2012 | 1005 | 0.060 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 286 | 0.060 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2004 | 13 | 0.060 |
Why?
| | Missouri | 3 | 2009 | 69 | 0.060 |
Why?
| | Tissue Adhesives | 1 | 2004 | 17 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2015 | 120 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2054 | 0.050 |
Why?
| | Colitis | 1 | 2006 | 241 | 0.050 |
Why?
| | Amifostine | 1 | 2002 | 1 | 0.050 |
Why?
| | Anesthetics, Combined | 1 | 2002 | 9 | 0.050 |
Why?
| | Radiation-Protective Agents | 1 | 2002 | 26 | 0.050 |
Why?
| | Anesthesia, Intravenous | 1 | 2002 | 14 | 0.050 |
Why?
| | Cytoprotection | 1 | 2002 | 56 | 0.050 |
Why?
| | Predictive Value of Tests | 4 | 2004 | 1949 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2023 | 70 | 0.050 |
Why?
| | Hemorrhoids | 1 | 2002 | 2 | 0.050 |
Why?
| | Surgical Staplers | 1 | 2002 | 4 | 0.050 |
Why?
| | Surgical Stapling | 1 | 2002 | 14 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2022 | 41 | 0.050 |
Why?
| | Abdomen | 2 | 2005 | 117 | 0.050 |
Why?
| | Pelvis | 3 | 2011 | 104 | 0.050 |
Why?
| | Patient Readmission | 3 | 2013 | 652 | 0.050 |
Why?
| | Intestinal Perforation | 2 | 2012 | 45 | 0.050 |
Why?
| | Specialties, Surgical | 1 | 2002 | 73 | 0.050 |
Why?
| | Prostheses and Implants | 1 | 2002 | 130 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 300 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2001 | 124 | 0.040 |
Why?
| | Pelvic Neoplasms | 1 | 2000 | 19 | 0.040 |
Why?
| | Hospitals, University | 2 | 2009 | 179 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 2879 | 0.040 |
Why?
| | Catheter Ablation | 1 | 2003 | 335 | 0.040 |
Why?
| | Databases, Factual | 2 | 2019 | 1266 | 0.040 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2000 | 74 | 0.040 |
Why?
| | Soft Tissue Neoplasms | 1 | 2000 | 112 | 0.040 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2020 | 64 | 0.040 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2020 | 54 | 0.040 |
Why?
| | Constipation | 1 | 2020 | 88 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2003 | 632 | 0.040 |
Why?
| | Uterine Prolapse | 1 | 2018 | 14 | 0.040 |
Why?
| | Forecasting | 2 | 2013 | 359 | 0.040 |
Why?
| | Leucovorin | 2 | 2014 | 69 | 0.040 |
Why?
| | Patient Selection | 2 | 1999 | 662 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2010 | 420 | 0.040 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1839 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2001 | 529 | 0.040 |
Why?
| | Colon | 1 | 2019 | 252 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2004 | 824 | 0.030 |
Why?
| | Ploidies | 1 | 1996 | 17 | 0.030 |
Why?
| | HIV Seropositivity | 2 | 2009 | 119 | 0.030 |
Why?
| | Intestine, Small | 2 | 2012 | 150 | 0.030 |
Why?
| | Endoscopy | 1 | 1999 | 285 | 0.030 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1996 | 53 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 75 | 0.030 |
Why?
| | Treatment Failure | 3 | 2007 | 339 | 0.030 |
Why?
| | Colonic Diseases | 1 | 1996 | 32 | 0.030 |
Why?
| | Pressure | 1 | 1996 | 237 | 0.030 |
Why?
| | Intraoperative Complications | 3 | 2003 | 129 | 0.030 |
Why?
| | Colorectal Neoplasms | 2 | 2003 | 752 | 0.030 |
Why?
| | Sensory Thresholds | 1 | 1994 | 32 | 0.030 |
Why?
| | Reflex | 1 | 1994 | 65 | 0.030 |
Why?
| | Palliative Care | 3 | 2012 | 706 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2014 | 41 | 0.030 |
Why?
| | Organ Sparing Treatments | 1 | 2014 | 32 | 0.030 |
Why?
| | Pouchitis | 1 | 2013 | 5 | 0.030 |
Why?
| | Neoplasm Invasiveness | 2 | 2008 | 483 | 0.030 |
Why?
| | Urinary Bladder Fistula | 1 | 2013 | 10 | 0.030 |
Why?
| | Cutaneous Fistula | 1 | 2013 | 13 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2016 | 3377 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2013 | 226 | 0.030 |
Why?
| | Remission Induction | 2 | 2004 | 271 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1095 | 0.020 |
Why?
| | Prognosis | 4 | 2004 | 3773 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 2003 | 399 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2013 | 230 | 0.020 |
Why?
| | Abscess | 1 | 2011 | 73 | 0.020 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2010 | 33 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Incidence | 2 | 2008 | 2636 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 478 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 1996 | 1173 | 0.020 |
Why?
| | Risk Factors | 3 | 2013 | 9746 | 0.020 |
Why?
| | Mitomycin | 1 | 2009 | 32 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2010 | 164 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 851 | 0.020 |
Why?
| | Hepatectomy | 1 | 2010 | 212 | 0.020 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2009 | 71 | 0.020 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2009 | 55 | 0.020 |
Why?
| | Chronic Disease | 1 | 1994 | 1716 | 0.020 |
Why?
| | Sex Factors | 2 | 2005 | 1965 | 0.020 |
Why?
| | Acute Disease | 1 | 2011 | 978 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1497 | 0.020 |
Why?
| | Inguinal Canal | 1 | 2006 | 10 | 0.020 |
Why?
| | Proctoscopy | 1 | 2005 | 5 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1691 | 0.020 |
Why?
| | Pain Measurement | 1 | 2008 | 506 | 0.020 |
Why?
| | Adolescent | 3 | 2010 | 20315 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2272 | 0.010 |
Why?
| | Blood Loss, Surgical | 1 | 2005 | 93 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1043 | 0.010 |
Why?
| | Cohort Studies | 2 | 2005 | 5409 | 0.010 |
Why?
| | Young Adult | 2 | 2010 | 12392 | 0.010 |
Why?
| | Washington | 1 | 2003 | 148 | 0.010 |
Why?
| | Anesthesia Recovery Period | 1 | 2002 | 12 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 295 | 0.010 |
Why?
| | Texas | 1 | 2003 | 228 | 0.010 |
Why?
| | Carcinoma | 1 | 2004 | 215 | 0.010 |
Why?
| | Midazolam | 1 | 2002 | 53 | 0.010 |
Why?
| | Propofol | 1 | 2002 | 60 | 0.010 |
Why?
| | Urinary Retention | 1 | 2002 | 20 | 0.010 |
Why?
| | Rome | 1 | 2001 | 1 | 0.010 |
Why?
| | Proctitis | 1 | 2001 | 6 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2002 | 167 | 0.010 |
Why?
| | Posture | 1 | 2002 | 175 | 0.010 |
Why?
| | Wound Healing | 1 | 2004 | 306 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2001 | 46 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1092 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2003 | 474 | 0.010 |
Why?
| | Outpatients | 1 | 2003 | 367 | 0.010 |
Why?
| | Pain, Postoperative | 1 | 2002 | 233 | 0.010 |
Why?
| | Recovery of Function | 1 | 2002 | 641 | 0.010 |
Why?
| | Vagina | 1 | 1999 | 174 | 0.010 |
Why?
| | Antidotes | 1 | 1999 | 136 | 0.010 |
Why?
| | Radiation Tolerance | 1 | 1996 | 98 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1997 | 610 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1432 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2002 | 2716 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2005 | 3386 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1997 | 867 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 5384 | 0.010 |
Why?
| | Reaction Time | 1 | 1994 | 410 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 1997 | 320 | 0.010 |
Why?
| | Melanoma | 1 | 1997 | 729 | 0.010 |
Why?
|
|
Birnbaum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|